Lumenis Be Ltd., a leading energy-based medical device company for aesthetic and eye care applications, announced new clinical data from its portfolio of industry-leading devices at the 45th Annual American Society for Laser Medicine and Surgery (ASLMS) Conference taking place in Savannah, Georgia from May 7-9. With Lumenis recognizing its 60th anniversary this year, the four scientific presentations underscore the company’s ability to harness cutting-edge laser technologies to exceed patient needs and outcomes, for both skin and hair loss concerns.
“At Lumenis, clinical evidence is the engine that drives our innovation forward. The data presented at ASLMS highlights our continued commitment to anticipating what’s next in aesthetics and transforming rigorous science into advanced, clinically validated solutions. As patient expectations continue to evolve, our focus remains on arming clinicians with the most cutting‑edge tools available, empowering them to deliver superior, consistent outcomes and confidently shape the future of patient care.”
Tzipi Ozer-Armon, CEO, Lumenis
FoLix Advances Clinical Validation with Studies Demonstrating Efficacy and Mechanism of Action
Two pivotal studies to be presented at ASLMS 2026 mark a significant milestone for FoLix, further validating its safety and efficacy as the first and only FDA-cleared non-ablative fractional laser treatment for hair loss. The first, led by Dr. Jennifer Krejci* (Limmer Hair Transplant Center, Texas), represents the largest randomized prospective study to date, demonstrating statistically significant improvements in terminal hair count, total hair count, and follicular density among androgenetic alopecia patients, with up to 82% showing measurable benefit. Complementing these findings, a second study led by Dr.
Neil Sadick* (Sadick Dermatology, New York) elucidates FoLix’s mechanism of action in human subjects, highlighting its ability to stimulate angiogenesis and dermal remodeling—key biological processes underlying treatment for hair loss.
ULTRApulse® CO2 Laser: Challenging Convention in Rhinophyma Treatment
Another oral presentation on the ULTRApulse Alpha device highlighted a clinical study** evaluating its use in the treatment of 15 patients with rhinophyma, a condition marked by nasal sebaceous gland hypertrophy and connective tissue fibrosis. While ablative lasers and oral isotretinoin are commonly used therapies, the optimal timing of isotretinoin in combination with laser treatment has previously been unclear. The presented abstract also discussed a unique combination of direct beam application with deep and superficial fractional scanners in treatment of rhinophyma. Results showed significant improvement in Rhinophyma Severity Index scores, 100% patient satisfaction, no delayed healing or abnormal scarring, and 100% of patients stating they would recommend the treatment.
Stellar M22™ XPL Repeat Mode: Faster, more comfortable Pulsed Light for Large-Area Treatments
The company’s e‑poster presentation highlights new clinical data showcasing advancements in Pulsed Light technology using the Stellar M22 platform for the treatment of large areas of photodamaged skin. The single‑center, prospective study evaluated a novel approach combining a high-frequency glide mode (up to 4 Hz) with traditional stamping that enables a smooth gliding technique for faster, more uniform treatments. Results demonstrated that this integrated XPL method was safe and effective in improving skin appearance and achieving lesion clearance across large surface areas, with no evidence of conventional striping or treatment‑related adverse events.
